Finoriq research workspace
Akari Therapeutics Plc (AKTX) Historical Metrics
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for. Review AKTX fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
- Company
- Akari Therapeutics Plc (AKTX)
- Ticker
- AKTX
- Market Cap
- $19.1M
- Latest Price
- $10.89
- Industry
- Biotech & Pharma
Akari Therapeutics Plc (AKTX) Current Valuation Metrics
Static valuation preview for Akari Therapeutics Plc (AKTX). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -121.7% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -47.3% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.6x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.